secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001005286-23-000059
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore Q2 FY2023 net loss $12.4M; revenue down 11% to $38.8M; initiates strategic alternatives review
--------------------------------------------------------------------------------

- Revenue $38.8M, down 11% YoY; net loss $12.4M vs net income $4.2M a year ago.
- Adjusted EBITDA $(0.4)M compared to $8.2M; Lifecore segment EBITDA $3.0M vs $9.1M.
- Board initiates strategic alternatives review; retains Morgan Stanley; contingent on lender forbearance.
- Signed term sheet with existing customer for substantial expansion including up-front payments.
- Development pipeline grew to 25 active projects; 3 projects received FDA approval, expanding commercial products to 29.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528623000059/0001005286-23-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528623000059/lndc-20230316.htm
  HTML page:      https://secwatch.observer/filing/0001005286-23-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer